Clinical Trial Update: Dietary Riboflavin (Vitamin B-2) and Cornea Cross-Linking [NA]

View source ↗

Summary

The clinical trial evaluating dietary riboflavin (vitamin B-2) as part of cornea cross-linking for keratoconus and corneal ectasia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Ectasia
• Keratoconus

Drugs mentioned

• Riboflavin (riboflavin)

Snippet

Sponsor: University of Missouri-Columbia | Conditions: Keratoconus, Cornea Ectasia | NA | Status: TERMINATED